Clinical Trial

Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2024 (before its estimated March 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This research is a clinical study with a single-blind randomized clinical trial design (randomized controlled trial) in RSCM-FKUI This study aims to Assess the effectiveness and safety of intradermal concentrated secretome injection therapy, triple combination cream, and intradermal tranexamic acid injection in melasma patients, determine the quality of life profile of melasma patients after triple combination cream therapy in melasma therapy, and determine SOD levels in melasma patients. This research will be attended by 90 research subjects
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06516419
Lead Sponsor Dr.dr.Irma Bernadette, SpKK (K)
Conditions Melasma
Enrollment 90 participants
Start Date 2024-02-13
Primary Completion 2025-03-30 (estimated)
Study Completion 2025-03-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-24